Search Within

Gunjan Lalitchandra Shah

  1. "Master of Science in Clinical and Translational Cancer Research "
Formats
  1. Meeting Abstract (122)
  2. Journal Article (57)
  3. Research Letter (8)
  4. Correspondence (1)
  5. Review (1)
Groups
  1. Bone Marrow Transplant (189)
  2. CTCR Scholars (189)
  3. Center for Hematologic Malignancies (189)
  4. Department of Medicine (189)
  5. Hematologic Malignancies, Division of (189)
  6. MSK Grad Students (189)

More Groups

People
  1. Miguel-Angel Perales (155)
  2. Parastoo Dahi (155)
  3. Michael Scordo (154)
  4. Sergio Giralt (148)
  5. Sean Devlin (125)
  6. Craig Sauter (80)

More People

Years
  1. 2025 (6)
  2. 2024 (16)
  3. 2023 (33)
  4. 2022 (22)
  5. 2021 (17)
  6. 2020 (36)

More Years

Publications
  1. Blood (53)
  2. Biology of Blood and Marrow Transplantation (47)
  3. Bone Marrow Transplantation (16)
  4. Transplantation and Cellular Therapy (16)
  5. Blood Advances (12)
  6. Clinical Lymphoma, Myeloma and Leukemia (5)

More Publications

Publishers
  1. Elsevier Inc. (72)
  2. American Society of Hematology (65)
  3. Nature Publishing Group (21)
  4. Taylor & Francis Group (4)
  5. Wiley Blackwell (4)
  6. American Society of Clinical Oncology (3)

More Publishers

Results (189)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparing gradings of immune effector cells toxicities: Application of ASTCT consensus grading system and implications for clinical management
    Meeting Abstract

    Pennisi, M.; Jain, T.; Mead, E.; Santomasso, B.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Maloy, M. A.; Devlin, S. M.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • EASIX and modified-EASIX are early predictors of severe cytokine release syndrome and neurotoxicity in patients treated with chimeric antigen receptor T cells
    Meeting Abstract

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J.; Maloy, M. A.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; Devlin, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact and safety of chimeric antigen receptor T cell therapy in vulnerable older patients with relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, J. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Early experience using radiotherapy as a salvage treatment for relapsed or refractory non-Hodgkin lymphomas following CD19 chimeric antigen receptor modified T-cell therapy
    Meeting Abstract

    Imber, B.; Palomba, M. L.; DeSelm, C.; Dahi, P. B.; Sauter, C. S.; Scordo, M.; Batlevi, C. L.; Park, J. H.; Shah, G. L.; Giralt, S. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
    Meeting Abstract

    Imber, B.; Palomba, M. L.; DeSelm, C.; Batlevi, C. L.; Dahi, P. B.; Giralt, S. A.; Noy, A.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Outpatient BEAM using daily etoposide and cytarabine with autologous hematopoietic stem cell transplantation for lymphoma is feasible and decreases inpatient length of stay
    Meeting Abstract

    Cazeau, N.; Cavalier, K.; Bhatt, V.; McElrath, C.; Lestrange, N.; Lachaud-Richard, M.; Inumerables, F.; Andrejko, M.; Batalha, J.; Cohen, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Pre-transplant fecal microbial diversity independently predicts critical illness after hematopoietic cell transplantation
    Meeting Abstract

    Adhi, F. I.; Littmann, E. R.; Taur, Y.; Maloy, M. A.; Markey, K. A.; Fontana, E.; Amoretti, L. A.; Wright, R.; Sanchez-Escamilla, M.; Castillo Flores, N.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Reducing symptom burden in older patients with multiple myeloma (MM) using interleukin-6 (IL-6) blockage peri-autologous hematopoietic stem cell transplantation (AHCT)
    Meeting Abstract

    Shah, G. L.; Kosuri, S.; Holder, J.; Hoover, E.; Chung, D. J.; Dahi, P. B.; Scordo, M.; Landau, H.; Giralt, S. A.
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save